{"id":296037,"date":"2025-12-15T00:00:00","date_gmt":"2025-12-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0014-2023-biopharma-atopic-dermatitis-atopic-eczema-access-reimbursement-access\/"},"modified":"2026-03-31T10:23:59","modified_gmt":"2026-03-31T10:23:59","slug":"acreim0014-2025-biopharma-atopic-dermatitis-atopic-eczema-access-reimbursement-access-reimbursement-atopic","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0014-2025-biopharma-atopic-dermatitis-atopic-eczema-access-reimbursement-access-reimbursement-atopic\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Atopic Dermatitis (US)"},"content":{"rendered":"<p>The treatment landscape for <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> in the United States is evolving rapidly. Since 2017, the <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr> has approved multiple agents, including systemic and topical <abbr data-abbreviation-entity=\"7988\" title=\"Janus kinase\">JAK<\/abbr> inhibitors, nonsteroidal topical therapies, and injectable biologics. New topical agents such as Arcutis\u2019s Zoryve and Incyte\u2019s Opzelura are expanding options for mild to moderate <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr>. For moderate to severe <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr>, the expanding treatment armamentarium includes IL-13 inhibitors (e.g., Sanofi \/ Regeneron\u2019s Dupixent, LEO Pharma\u2019s Adbry, Eli Lilly \/ Almirall\u2019s Ebglyss), systemic <abbr data-abbreviation-entity=\"7988\" title=\"Janus kinase\">JAK<\/abbr> inhibitors (e.g., Pfizer\u2019s Cibinqo, AbbVie\u2019s Rinvoq), and an IL-31 inhibitor (Galderma\u2019s Nemluvio). In December 2024, the <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr> approved Organon\u2019s topical Vtama\u00a0for mild, moderate, and severe <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr>. Although Dupixent has largely established its position in <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> treatment, payer policies affecting more recently approved therapies will influence physician prescribing and patient access to newer therapies.<\/p>\n<p><b>QUESTIONS ANSWERED<\/b><\/p>\n<ul class=\"round-bullets\">\n<li>What are the current prescribing practices for <abbr title=\"atopic dermatitis\">AD<\/abbr>, and how are they impacted by payer policy?<\/li>\n<li>What are dermatologists\u2019 and payers\u2019 opinions of recently approved therapies, and how has their availability for <abbr title=\"atopic dermatitis\">AD<\/abbr> impacted physician prescribing and payer reimbursement?<\/li>\n<li>How will dermatologists\u2019 prescribing of established agents by line of therapy shift as these new agents are incorporated into the treatment algorithm?<\/li>\n<li>As systemic <abbr title=\"Janus-activated kinase\">JAK<\/abbr> inhibitors are granted label expansions for <abbr title=\"atopic dermatitis\">AD<\/abbr>, what do payers say about the use of indication-based formularies?<\/li>\n<li>What are payers\u2019 and dermatologists\u2019 perspectives on promising emerging agents such as Kyowa Kirin \/ Amgen\u2019s rocatinlimab, Sanofi\u2019s amlitelimab, and Otsuka \/ Acrotech\u2019s difamilast?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS <\/strong><\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary Research:<\/strong> Survey of 100 U.S. dermatologists. Survey of 30 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s).<\/p>\n<p><b>Fingertip Formulary: <\/b>Formulary coverage by commercial plans covering 164.3 million lives nationally.<\/p>\n<p><b>Real-world data:<\/b> U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key Drugs Covered: <\/strong>Adbry, Cibinqo, Dupixent, Eucrisa, Opzelura, Rinvoq, Ebglyss, Nemluvio, Zoryve, Vtama, Rocatinlimab, Amlitelimab, Difamilast.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Identify and learn how to overcome roadblocks to market access to best position your brand.<\/li>\n<li>Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.<\/li>\n<li>Evaluate competitor strategies for securing favorable market access terms.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296037","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296037\/revisions"}],"predecessor-version":[{"id":575260,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296037\/revisions\/575260"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}